Latest Interviews

Global Capital Markets: Deflation or Stabilization?

Thomas Finke, Afsaneh Beschloss, Mohamed El-Erian, David Harding, Joseph Hooley, Steven Tananbaum, Tom Fink, Jay Holey

Panelists including Jay Holey, Mohammed Al-Arain, and Steve Tannenbaum analyzed the global economy's structural slowdown and the divergent trajectories of advanced and emerging markets, noting that while central banks face policy limits, emerging economies retain fiscal capacity for growth. The discussion highlighted China's critical transition from an export-led model to a consumption-driven one, alongside the disruptive impact of fintech and digital platforms on traditional productivity metrics and banking infrastructure. Despite near-term political uncertainties like Brexit and anti-establishment movements, experts identified specific investment opportunities in distressed credit, quasi-sovereign bonds, and sectors combining digital innovation with unique content.

Thematic Investing and Portfolio Strategies: Betting on the Megatrends

Stephen Foley, Victor Chu, Taimur Hyat, Catherine Keating, Rebecca Patterson, Mike Ramsay, Timer Hyatt

Global megatrends in aging demographics, rapid urbanization, and geopolitical shifts toward a Chinese-led economy are fundamentally reshaping capital flows and demanding a transition to lower-carbon energy systems. Industry experts identify private markets, long-term infrastructure, and cross-asset task forces as critical vehicles for capturing value in healthcare, automation, and cybersecurity while navigating the risks of de-globalization and premature market entry. Successful execution requires patient capital with horizons extending five to twenty-five years, emphasizing rigorous due diligence to distinguish viable commercial solutions from speculative bubbles in emerging and developed sectors alike.

Bringing 21st Century Medicine to America's Veterans

Jonathan Simons, Matthew Collier, Magali Haas, Matthew Rettig, Mark Simon

The Department of Veterans Affairs has established a Senior Advisor for Strategic Partnerships to shift from isolated operations to a collaborative model leveraging its $169 billion budget and unique longitudinal data assets. By partnering with entities like Cohen Veterans Bioscience and private biotech firms, the agency is accelerating research on traumatic brain injury, suicide prevention, and precision oncology, evidenced by successful treatments for advanced prostate cancer patients. These initiatives aim to de-risk clinical trials, improve patient access to novel therapies, and transform the VA into a premier engine for precision medicine by overcoming historical cultural barriers to external collaboration.

Leaders of Companies that are Changing the World

Josh Barro, John Mackey, Strive Masiyiwa, Blake Mycoskie, Kristin Groos Richmond

John Mackey, Strive Masiwa, Blake Mycoskie, and Kristen Grues-Richmond convened to argue that stakeholder synergy and shareholder value are simultaneous goals rather than tradeoffs, exemplified by Whole Foods' Conscious Capitalism framework, TOMS' supply-chain pivot, and Revolution Foods' employee equity model. The panel detailed how these leaders utilize B Corporation certification and localized operations to achieve cost parity with public programs while navigating the regulatory complexities of public versus private market status. Ultimately, the discussion concluded that aligning business missions with societal needs drives long-term profitability and talent retention, urging companies to prioritize customer storytelling over traditional paid media to verify their impact.

Meaningful Work and Relationships: A Conversation with Ray Dalio

Ray Dalio, Raymond Dalio, Robert Kegan, Bob Keegan, Ken Broad, Collin Tate, Larry, Amanda Pullinger, Lewis, Hania Sadat

Bridgewater Associates operates as a globally scaled firm of 1,500 employees built on Ray Dalio's philosophy of radical truth and transparency to drive an idea meritocracy. The organization utilizes data-driven tools like the "Dot Collector" app and believability-weighted decision-making systems to systematically surface conflicts and resolve them through structured feedback. This unique model prioritizes individual development and psychological adaptation over traditional hierarchies, enabling the firm to navigate market crises while generating over two million downloads of its codified decision-making principles.

Why OCaml

Approximately a decade ago, Jane Street adopted OCaml as its primary functional programming language to secure C-like performance and rigorous type safety while maintaining development conciseness. This strategic choice serves as a filtering mechanism for hiring, attracting highly motivated engineers through a specialized one-month training program that results in a consolidated, high-performing workforce. Although the firm faces ecosystem limitations compared to mainstream languages, the implementation of a single language across its multi-billion-dollar systems enables significant code reuse and shifts the priority from empirical testing to the universal guarantees of static type checking.

Effective ML 2011 Harvard CS51 Part 1

Ron Minsky

Ron Minsky, a technical leader at Jane Street Capital, presented a comprehensive case for prioritizing code correctness and maintainability through strict OCaml design principles that leverage the type system to enforce data invariants and ensure pattern match exhaustiveness. The lecture outlined specific architectural strategies, including mandatory interfaces, uniform naming conventions, and a "reader-over-writer" philosophy, which collectively minimize cognitive load and prevent silent failures in high-stakes financial systems. Additionally, the speaker addressed immediate course logistics by extending the Moogle project description deadline and recommending simple list-based implementations to avoid unnecessary debugging complexity.

Caml Trading

Carl Curry, Ron Minsky

Jane Street Capital, a proprietary trading firm operating in four global cities, transitioned its primary development stack to the functional programming language OCaml to satisfy critical demands for absolute correctness, high performance, and code maintainability. This adoption enables the firm's 35 core developers to leverage OCaml's powerful type system and algebraic data types for static exhaustiveness checks, ensuring the rigorous standards required to process billions of dollars in daily equity trades without error. While the language presents challenges in ecosystem maturity, the firm has actively mitigated these gaps through its Jane Street Summer Project and achieved superior hiring outcomes by attracting engineers skilled in functional paradigms.

Seven Implementations of Incremental

Incremental is an internal OCaml library that efficiently refreshes large computations by modeling logic as a dependency graph, allowing localized updates when only small data subsets change. Through eight iterative development phases, the team resolved critical academic limitations regarding garbage collection and dynamic graph restructuring, culminating in a production-ready V8 implementation that achieved a threefold speedup using generalized algebraic data types. This technology successfully transformed a slow trading system frontend into the suite's fastest application and is now being explored for reactive JavaScript compilation and efficient functional data structure diffing.

Public Health, Medical Research and the Cancer Moonshot: A Collaboration to Change the World

Michael Milken, Francis Collins, Linda Fried, Robert Hugin, Freda Lewis-Hall

Vice President Biden and medical leaders are launching a strategic "Cancer Moonshot" to overcome siloed research through a $680 million federal investment and the Precision Medicine Initiative's enrollment of one million Americans. The framework prioritizes seven key themes, including early detection blood tests, single-cell analysis, and public-private partnerships modeled after the Accelerating Medicines Partnership, while explicitly warning against overpromising a timeline for a universal cure. Parallel to the National Institutes of Health and FDA funding, the initiative integrates public health science to address prevention drivers and leverages global data collaboration to accelerate the shift toward data-driven, individualized cancer therapies.

Public Health Summit Dinner March 2, 2016

Mike Milken, Tom Frieden, Rob Califf, Fred Upton, Nancy Pelosi, Francis Collins

This event featured key figures including Francis Collins, FDA Commissioner Rob Califf, and CDC Director Tom Frieden discussing critical public health challenges such as the implementation gap between knowledge and action, rising opioid overdose deaths, and the threat of a post-antibiotic era. The proceedings highlighted specific policy responses ranging from Mexico's successful food taxes and "health stops" to the U.S. House passing the 21st Century Cures Act and funding the Brain Initiative, alongside clinical breakthroughs in treating depression and heart failure. To address these systemic issues, officials urged for robust funding, the adoption of global "find, stop, prevent" strategies, and a massive volunteer effort for the Precision Medicine Initiative to accelerate biomedical discovery.

The Promise of Public Health

Mike Klowden, Richard Besser, Nancy Brown, Thomas Farley, Joseph Jimenez, Fred Upton

The Milken Institute's inaugural Public Health Summit convened key industry and government leaders, including Novartis CEO Joe Jimenez, CDC Director Tom Frieden, and Congressman Fred Upton, to advocate for elevating disease prevention alongside medical cures. Participants analyzed critical strategies such as conditional reimbursement models, real-time data utilization, and the "21st Century Cures Act" to address looming challenges posed by an aging global population and stagnant biotech venture capital. The consensus emphasized that sustainable health outcomes require shifting from volume-based treatment to outcome-based policies that integrate genomics, behavioral interventions, and bipartisan legislative support to bridge significant disparities in US public health metrics.

Infectious Diseases: Staying One Step Ahead

Michael Gerson, Michael Kurilla, Vanina Laurent-Ledru, Pranav Shetty, Moncef Slaoui

Experts including Vanina Laurent Ledru of Sanofi Pasteur and Monsef Slaoui of GSK advocate shifting global health strategy from reactive outbreak response to proactive prevention to counter drivers like climate change and increased mobility. Leveraging platform technologies and industrial-scale manufacturing, the industry aims to bypass the traditional decade-long vaccine development cycle for threats such as Ebola, Zika, and pandemic flu while addressing critical gaps in local infrastructure and surveillance. Despite improvements in specific regions, the panel concludes that long-term consistency in funding and international cooperation is essential to prevent future crises from overwhelming fragile health systems.

The Health of Nations: Meeting the Sustainable Development Goals

Matthew Bishop, David Barash, Stefano Bertozzi, Deborah Birx, Jacqueline Shea

A panel of global health experts and industry leaders convened to evaluate the gap between current Social Progress Index trajectories and the ambitious targets set by the UN Sustainable Development Goals. The discussion highlighted critical failures in data granularity, vaccine development funding, and the unique health crises facing high-income nations like the United States. Experts concluded that achieving these goals requires a strategic pivot from charity-based models to shared-value ecosystems driven by granular data, impact investing, and cross-sector innovation.

Lunch Program │ An Update on Zika Virus With CDC Director Tom Frieden

Tom Frieden, Mike Klowden, Michael Gerson, Lynn Goldman

CDC Director Thomas Frieden and other health experts highlight that public health interventions have driven a disproportionate share of modern economic growth by dramatically extending life expectancy through vaccines, global partnerships, and improved chronic disease management. Addressing current threats like Zika, the speakers emphasize accelerated testing capabilities and the Global Health Security Agenda's accountability framework while contrasting rapid biological changes in life spans with slower genetic evolution. The presentation further illustrates how environmental factors, epigenetics, and escalating portion sizes significantly influence health disparities and disease rates independent of genetics.